Rational use of expensive medicines in the Netherlands: strategies to improve effectiveness and reduce burden on patients and society – a narrative review Authors: Bart MF Penninx, Sander W Tas, Lonneke Timmers, Nicole CAJ van de Kar, Atse Huisman, Denise van den Berg, Zoé LE van Kempen, Carla EM Hollak Published: 2026 ABSTRACT AbstractBackgroundWhile new expensive medicines often offer substantial benefits to patients, they can carry inherent drawbacks such as uncertainty regarding efficacy translating into effectiveness, safety and rational use, as well as a substantial financial burden on society and/or patients. Rational use of medicines aims to maximize effectiveness whilst minimizing side effects, patient burden, and societal costs. In the Netherlands, initiatives aiming to improve the rational use of expensive medicines are being carried out with increasing frequency and in a programmatic manner. This review identified the strategies used, and includes a structured approach for their application during the medicine’s use in clinical practice.Main bodyRational use initiatives, driven by clinicians and pharmacists, and funded by the Dutch Ministry of Health and the Dutch health insurers were evaluated for strategies that aim to improve the rational use of expensive medicines. In addition, a non-systematic narrative review was carried out through searches in Google, Google Scholar, Pubmed, the Artificial Intelligence (AI)- tools Global Campus and Evidence Hunt to identify additional strategies. Identified strategies were categorized by assessing whether they aimed to address the efficacy-effectiveness gap or to reduce the side effects and societal burden of expensive medicines. Thirteen strategies to improve rational use were identified. Two strategies were identified that aim to address the efficacy-effectiveness gap: optimize patient selection and generating evidence on clinical endpoints. 11 additional strategies that aim to reduce side effects or societal burden were identified: dose reduction, personalized dose optimization, interval lengthening, shortening of the treatment duration, biosimilar/generic drug use, non-medical drug switching, reduction of additional non-medication costs, reduction of drug wastage, switching the route of administration, boosting (improve drug exposure and/or reduce the dose by influencing pharmacokinetic parameters through co-interventions), and optimization of medication adherence.ConclusionsRational use of expensive medications is essential as part of a drug’s life cycle and can benefit patients as well as society. The framework and strategies described in this overview provide guidance for the future rational use of expensive medicines, both for those already in use and for those newly introduced.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12916-026-04897-7.Keywords: Rational use, Efficacy-effectiveness gap, Expensive medicines, Societal burden, Access Background The introduction of medicines often comes with hopeful prospects for patients. In the last decades, many new drugs with great impact have been introduced. Although many medicines have brought substantial benefits to patients, they are often accompanied by drawbacks. New medicines often involve uncertainties regarding their use in clinical practice. In the last decades, the European Medicines Agency (EMA) and the American Food and Drug Administration (FDA) have increasingly prioritized early marketing authorisation, particularly in the fields of rare diseases and oncology. An increasing proportion of approvals by the FDA and EMA in these fields is based on early-phase clinical trials and surrogate endpoints [1–3]. Although early access can benefit patients, these approvals often leave questions regarding the translation of trial efficacy into real world effectiveness and rational use unanswered at the time of market introduction. Limited generalizability of study populations to patients encountered in clinical practice further contributes to the efficacy-effectiveness gap [4]. As a result, there is uncertainty about which patients are most likely to benefit from the medicine at what stage of the disease. In addition, new medicines may cause side effects and also frequently impose a financial burden on healthcare, and/or patient’s personal budgets [5, 6]. Rational use is defined by the World Health Organization (WHO) as “Patients receiving medications appropriate to their clinical needs, in doses that meet their own individual requirements, for an adequate period of time, and at the lowest cost to them and their community.”[7] It refers to the use of a medicine in clinical practice, and is therefore positioned after marketing authorisation and a positive recommendation for reimbursement from a Health Technology Assessment (HTA) body. The WHO’s definition and program on the rational use of medicines originated in the 1980s [8]. The WHO-program focuses primarily on establishing the basic infrastructure to support evidence based medicine in low-resource settings, naturally leading to a more efficient use of resources and, consequently, to improved health outcomes [8, 9]. However, in recent years, the rapid expansion of therapeutic possibilities and rising costs have introduced scarcity even in high-resource settings, underscoring that rational use of medicines is a globally pressing challenge rather than one limited to low-resource settings. Rational use ensures that medicines are administered only when they truly benefit the patient, to the exact extent necessary. Therefore, rational use not only reduces side effects and patient burden, but also safeguards the sustainability of our healthcare systems and ensures access to future therapies. In the Netherlands, the Dutch Ministry of Health and the Dutch health insurers are actively supporting and funding investigator-initiated research and implementation projects focused on the rational use of medicines through a programmatic approach. The goal of rational use is to achieve better patient outcomes while maintaining or reducing costs or reducing cost while maintaining or improving patient outcomes. To improve rational use, several strategies can be implemented, including conducting post-marketing studies. These studies may address remaining questions about real-world effectiveness, helping to address the efficacy-effectiveness gap, or evaluate strategies to reduce side effects and the patient and societal burden of proven effective medicines. The objective of this narrative review was to identify and describe the strategies that can be used to improve the rational use of authorized and available expensive medicines and to provide a structured framework for their application in clinical practice. We thereby seek to encourage especially clinicians to reflect on their prescribing of expensive medicines and identify opportunities for more rational use. Main text Search strategy and selection criteria Initiatives funded by the ongoing rational use programs in the Netherlands, which were funded by the Dutch Ministry of Healthcare (ZonMW Rational Pharmacotherapy Program, active since 2012 (https://www.zonmw.nl/nl/programma/goed-gebruik-geneesmiddelen), or the Dutch health insurers (the Treatmeds foundation, active since 2021 (https://treatmeds.nl/), and the GIDS-program, active since 2022 (https://www.umcnl.nl/projecten/dure-geneesmiddelen-betaalbaar-houden/)), were searched to identify strategies promoting rational use of expensive medicines, in accordance with the WHO-definition [5]. To identify additional strategies, we carried out a non-systematic literature review. Google, Google Scholar, Pubmed, and the Artificial Intelligence (AI)- tools Global Campus and Evidence Hunt were utilized as search engines, and reference lists of identified studies were screened. When using the AI tools, the WHO definition of rational use of medicines was provided as context, and the tools were prompted to identify strategies to improve rational use according to this definition. Searches were conducted for medicines in general and separately for expensive or innovative medicines. The publications identified by these tools were reviewed. No geographic restrictions were applied to the search strategy. A list of used search terms is available in the supplementary data. Searches were last performed in March 2025. As our aim was to identify strategies beyond those already identified in existing rational use programs, we used broader search terms related to rational use and cost containment rather than terms for specific strategies in Google, Google Scholar and Pubmed. The search strategy included terms related to both rational use of medicines in general and expensive or high-cost medicines, in order to capture a broad range of relevant initiatives. Identified strategies were included if they could be applied to medicines that we considered expensive. No strict definition was applied. For illustration, in the Dutch context, medicines costing more than €1,000 per patient per year are often regarded as expensive, as exceeding this threshold triggers a different reimbursement system. Included strategies were categorized based on the timepoint in the use in clinical practice when its implementation is most relevant. To do so, we assessed whether the strategies addressed the efficacy–effectiveness gap or included approaches aimed at improving rational use by reducing the burden on patients or society. Results Thirteen strategies that aim to improve the rational use of expensive medicines were identified. These strategies were identified from ongoing rational use initiatives in the Netherlands, and from three publications (van der Togt et al. 2023, Serritella et al. 2020, Zietse et al. 2024) [10–12]. The strategies and their definitions are presented in Table 1. Table 1Identified strategies to improve the rational use of expensive medicines and their definitionsStrategyDefinitionOptimize patient selectionTo restrict treatment to patients for whom a clinically relevant benefit can be expected, based on predefined start criteria. For chronic treatments, predefined stop criteria should be applied to discontinue therapy whenever a clinically relevant benefit is no longer expected.Generate evidence on clinical endpointsTo generate evidence on relevant clinical endpoints when effectiveness in a ‘real world’ population is too uncertain.Reduce the doseTo reduce the dose of a medicineExtend the intervalTo increase the amount of time between two administrations of a medicine.Shorten the treatment durationTo reduce treatment duration for medicines with established benefit, while maintaining clinical effectivenessApply personalized dose optimizationTo dose a medicine based on personal characteristics of the patient (-, biomarker-, renal function-, imaging-, weight guided dosing)Switch the formulation or the route of administrationTo switch to a more favourable formulation or route of administration of the same active substanceBoost the drugTo improve drug exposure and/or reduce the dose by influencing pharmacokinetic parameters through co-interventions.Improve patients’ use and medication adherenceTo make sure patients take their medication in the right way, at the right time and in the proper doseUse biosimilar/generic drugsTo select the lowest-cost variant among medicines with the same active substance.Switch drugs for non-medical reasonsTo switch to another medicine with equal effectiveness and safety primarily for cost-reduction.Reduce additional non-medication costsTo reduce the costs of a treatment by reducing non-medication expenditure such as staff, equipment or facility related costs.Reduce drug wastageTo minimize the quantity of drugs that are not used by patients. Identified strategies to improve the rational use of expensive medicines and their definitions A structured framework for the application of these thirteen strategies during the medicine’s use in clinical practice is provided in Fig. 1. Two strategies were identified that aim to address the efficacy-effectiveness gap, which are optimize patient selection and generating evidence on clinical endpoints. Eleven strategies were identified that aim to reduce the burden of medicines on patients and society. In the supplementary data, successful or ongoing dutch initiatives that applied these strategies on improving the rational use of expensive medicines are highlighted. For five out of thirteen identified strategies no suitable example could be found within ZonMW GGG, Treatmeds and GIDS. In those cases, we described other Dutch initiatives outside these programs to provide an overview of how the different rational-use strategies have been applied nationally. Framework for the application of rational use strategies during the medicine’s use in clinical practice. Legend: When there is insufficient certainty that efficacy will translate into effectiveness, rational use should prioritize generating the missing evidence, as optimal outcomes depend on accurate determination of the indication. After effectiveness is sufficiently established, with regard to patient selection, start and stop criteria and clinical endpoints, the goal of rational use shifts to limit avoidable side-effects, patient burden and costs. The 11 strategies that can be employed to reach this goal are displayed on the right, covering a spectrum from improving patient care (top) to cost reduction (bottom), though most affect both Conclusions This review identified 14 different strategies that can be deployed to improve rational use of expensive medicines. The program on rational use by the WHO focuses primarily on how evidence-based medicine can be effectively implemented within low-resource settings [9, 13]. However, studies and initiatives that focus on enhancing rational use of expensive medicines fit well with this definition, rendering it still highly relevant today, both in low- and high-resource settings [7]. The initiatives as detailed in the supplementary data indicate that rational use of expensive medicines is an area of great potential, demonstrating that improvement in patients’ wellbeing and societal costs savings can be pursued simultaneously. Some of these initiatives have already demonstrated success, while others are still ongoing and require further evaluation. There are also examples of studies that proved unsuccessful, such as administering pomalidomide to multiple myeloma patients at 4 mg every other day instead of 2 mg once daily. While this regimen could have halved costs due to flat pricing, it led to suboptimal pharmacokinetic and pharmacodynamic outcomes [14]. Another unsuccessful example is the prematurely terminated DOT-MS study, in which discontinuation of first-line disease-modifying therapy in patients with stable Multiple Sclerosis (MS) led to increased recurrent inflammation [15]. When cost-reduction is the sole aim of a rational use initiative, patient safety and effectiveness should not be compromised. If the goal is to improve patient care as well, the choice of strategy depends on the level of confidence that the medicine’s proven efficacy for a specific indication translates into effectiveness in clinical practice. If this is the case, less intensive or more patient-centered regimens can be investigated and compared to a well-established standard of care. As shown in the results and illustrated by the examples in this literature review, there are specific opportunities for medicines used in the treatment of chronic conditions for which therapy for life or until treatment failure is advocated. In these cases, dose reductions, personalized dosing or interruption of treatment can both benefit patients and result in cost reductions [16, 17]. However, we argue that when uncertainty whether efficacy will translate into effectiveness is a mayor issue, key uncertainties regarding clinical outcomes, patient selection, and start and stop criteria must first be resolved before these adaptations can be made. This may be particularly relevant for new orphan medicines or oncological drugs, as many of these drugs demonstrate uncertain added clinical benefit on a group level at the time of introduction [3, 18]. We fully recognize that rational use is only relevant for medicinal products that have received a marketing authorisation and a positive opinion from a Health Technology Assessment (HTA) body, and have therefore already successfully passed regulatory evaluation. The restriction of rational use to authorized medicines that received a positive opinion by a HTA-body does not preclude that considerations regarding rational use may be an integral part of the HTA evaluation process and subsequent managed entry agreements, which are agreements between payers and manufacturers to allow access to new medicines under predefined conditions. There is an increasing number of new medicines that meet genuine unmet needs and have the potential to drastically improve prognosis, while questions about whether efficacy will translate into effectiveness remain, sometimes because large randomized controlled trials (RCT)s may be unethical, unfeasible or because the RCT was conducted in an overly broad patient population [19]. For these medicines, creating pathways such as the Dutch Orphan Drug Acces Protocol (ODAP), that allow for early access can be important [20]. The ODAP combines a managed entree agreement with rational use research to increase effectiveness and cost-effectiveness. This way rational use can contribute to quick access for both patients and manufacturers. Several emerging strategies may substantially improve patient care and affordability of medicines in the future. Advances in predictive models may enable better estimation of treatment benefits. For example, patient-derived organoids are used to assess drug responsiveness ex-vivo, trying to predict more precise patient selection. This approach has the potential to reduce unnecessary toxicity and avoid ineffective, costly treatments [21]. The current review focuses on concrete strategies to improve the rational use of authorized and reimbursed medicines. However, beyond this scope, promising initiatives in which improvements in patient care and cost savings go hand in hand also exist. Hospital-developed cell and gene therapies could provide advantages compared with commercially produced alternatives in terms production speed, access and affordability [22–24]. In addition, magistral compounding using the active substance from authorized medicines can improve access and affordability when commercially available products are unavailable and can also improve treatment suitability through patient-specific formulations [25]. Lastly, shared decision-making is an essential component of clinical practice, enabling patients to make well-informed choices that reflect their values and preferences; this may include deciding not to pursue treatments with considerable side effects or modest expected benefit, which may enhance patient satisfaction and reduce unnecessary costs. Studies that apply the strategies outlined in this review are typically initiated by healthcare professionals and funded by public money. Pharmaceutical companies are responsible for demonstrating the efficacy of their medicines, while promoting their rational use should be a shared responsibility between the companies and society. As marketing authorisation holders have exclusive rights to apply for label changes, newly generated rational use insights are seldomly incorporated in the label. The proposed European Union (EU) Pharmaceutical Regulation suggested to allow “an entity not engaged in an economic activity”, such as academia, to submit evidence that may require the marketing authorization holder to update the label with a new therapeutic indication (Article 48 of the Regulation [26].). We expect that this regulatory amendment is insufficient and that modifications concerning rational use, submitted by non-profit institutions, should likewise be permitted and formally integrated into the product labeling. Pharmaceutical companies have limited incentive to prioritize the rational use of expensive medicines, as this could result in lower sales. However, there are also examples of pharmaceutical company initiatives that have led to improved outcomes and cost savings, as illustrated by Bristol-Meyers Squibb with their sponsorship of the investigator-initiated NADINA study [27]. This study compared a short period of immunotherapy before surgery for stage III melanoma with a much longer and therefore more expensive standard treatment after surgery. The study showed that 59% of patients in the intervention group indeed did not require prolonged immunotherapy after surgery [27]. Although the NADINA study evaluated a not yet approved indication and therefore falls outside the strict definition of rational use used here, research into a new indication area can certainly serve the same purpose. Similar to pharmaceutical companies, other stakeholders may also have additional interests beyond patient care. We argue that these benefits are mostly complementary to the purpose of rational use. Clinicians may benefit from rational use research to strengthen their academic careers, whereas health insurers aim to control costs, while being legally required to ensure adequate access to high-quality care. A potential drawback of rational use initiatives and studies is that pharmaceutical companies can respond to expected declines in sales volume by charging higher prices upon market entry. It is important to anticipate such situations, for example, by carefully designing pricing strategies. Furthermore, healthcare systems should enable rational use by removing conflicting financial interests for both physicians and hospitals, with incentives aligned to high-quality care and cost containment. When designing rational use studies, the involvement of healthcare professionals as well as patients is essential to agree upfront on the level of evidence that is required. The early involvement of patient organizations in study design is critical; investigators should communicate potential risks transparently and integrate patient-informed perspectives to enhance alignment with patient needs and priorities. Additionally, the involvement of clinical pharmacists is essential for initiatives using strategies such as boosting or dose reduction. Involvement of all stakeholders will enable a shared strategy to secure implementation of the results and increase the value of medicines during the medicine’s use in clinical practice, in order to improve value for patients and society. We believe that the current Dutch approach of funding investigator-initiated rational use initiatives programmatically and involving all relevant stakeholders could serve as an exemplary model. Our review has several shortcomings. By mainly focusing on successful examples, our non-systematic approach may have overlooked certain challenges or limitations of rational use. For several of the examples described in the supplementary data, comparative data on clinical effectiveness or costs were not available. As a result, the overall impact of these strategies on population-level health outcomes and on healthcare expenditures for a healthcare system is not always clear. Another limitation of our review is that we exclusively described examples from the Netherlands, as rational use studies can be readily identified through dedicated funding programs. However, collaborative programs involving healthcare professionals and payers to improve the rational use of expensive medicines may also exist in other countries, but are not easily retrieved by our search strategy and would require another methodological approach, such as sending out a questionnaire to relevant national stakeholders. As a result, strategies other than the 13 described in this review that might be applied in these countries may have been missed. The absence of a universally accepted term for rational use of expensive medicines made it unfeasible to systematically identify all strategies that promote rational use. We therefore propose applying the WHO definition in a broader context than how it has been used to date. In conclusion, this review highlights the potential of Dutch initiatives aimed at improving the rational use of expensive medicines, driven by collaboration between healthcare professionals and payers. We call on the scientific community to contribute to research and to implement rational use strategies. Rational use studies can secure the sustainability of our healthcare systems and ensure access to future medicines. True improvement in patient care will not be achieved through new medicines alone, rational use of these medicines is essential as well. Electronic Supplementary Material Below is the link to the electronic supplementary material. Supplementary Material 1: Supplementary file 1 Acknowledgements Not applicable. Abbreviations European Medicines Agency Food and Drug Administration World Health Organization Health Technology Assessment Artificial Intelligence Orphan Drug Access Protocol Randomized Controlled Trial European Union Multiple Sclerosis Authors’ contributions BMFP developed the methodology, carried out the search, collected and interpreted the identified initiatives and manuscripts, visualized the data, and wrote the original draft, all under the direct supervision of CEMH. NCAJvdK, SWT, LT, AH, DvdB and ZLEvK have substantially revised the manuscript. All authors read and approved the final manuscript. Funding No specific funding was received for this study. BMFP is employed through an unrestricted grant from the Amsterdam Research Centre for Health Economics (ARCHE), a collaboration between Amsterdam UMC, the Faculty of Economics and Business of the University of Amsterdam, and SEO Amsterdam Economics. Data availability All data generated and/or analysed during the current study are included in the published study. Declarations Ethics approval and consent to participate Not applicable. Consent for publication Not applicable. Competing interests CEMH is a member of the Advisory Committee to the insured healthcare package (Dutch Healthcare Institute), chair of Medicines for Society and member of round table on orphan drugs (Dutch Healthcare Institute). NCAJvdK has received consulting fees from Samsung, Roche and Alexion and payments or honoraria from Sobi and Novartis. BMFP, SWT, LT, AH, DvdB, ZLEvK have nothing to disclose. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1: Supplementary file 1 Data Availability Statement All data generated and/or analysed during the current study are included in the published study.